Q3 Asset Management’s AbbVie ABBV Stock Holding History

Q3 Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,545	Closed	-$1.06M	–	40
2022 Q1	$1.06M	Sell	6,545 -574	-8%	-$83.4K	0.49%	26
2021 Q4	$964K	Buy	+7,119	New	+$841K	0.41%	25

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Q3 Asset Management's ABBV Position: Q2 2022 in Review

Q3 Asset Management sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 6,545 shares — an estimated $1.06M sold.

Q3 Asset Management first reported a position in ABBV in Q4 2021 and held it in 2 quarters. The position peaked at $1.06M in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Q3 Asset Management reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Q3 Asset Management sold 6,545 AbbVie shares in Q2 2022, an estimated $1.06M.
Q3 Asset Management first reported a position in AbbVie in Q4 2021 and held it in 2 quarters.
Q3 Asset Management's AbbVie position peaked at $1.06M in Q1 2022.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Q3 Asset Management's 13F filing for Q2 2022, filed 2 Aug 2022.